Acrivon Therapeutics Inc (NASDAQ: ACRV)’s stock price has decreased by -12.56 compared to its previous closing price of 1.99. However, the company has seen a -3.87% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-25 that Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically
Is It Worth Investing in Acrivon Therapeutics Inc (NASDAQ: ACRV) Right Now?
Additionally, the 36-month beta value for ACRV is 1.73. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACRV is 21.74M and currently, short sellers hold a 4.08% ratio of that float. The average trading volume of ACRV on April 25, 2025 was 182.06K shares.
ACRV’s Market Performance
ACRV stock saw a decrease of -3.87% in the past week, with a monthly decline of -33.33% and a quarterly a decrease of -68.07%. The volatility ratio for the week is 11.31%, and the volatility levels for the last 30 days are 21.60% for Acrivon Therapeutics Inc (ACRV). The simple moving average for the last 20 days is -1.50% for ACRV stock, with a simple moving average of -72.90% for the last 200 days.
Analysts’ Opinion of ACRV
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see ACRV reach a price target of $16. The rating they have provided for ACRV stocks is “Buy” according to the report published on September 16th, 2024.
ACRV Trading at -54.59% from the 50-Day Moving Average
After a stumble in the market that brought ACRV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.09% of loss for the given period.
Volatility was left at 21.60%, however, over the last 30 days, the volatility rate increased by 11.31%, as shares sank -29.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.51% lower at present.
During the last 5 trading sessions, ACRV fell by -1.67%, which changed the moving average for the period of 200-days by -75.04% in comparison to the 20-day moving average, which settled at $1.7685. In addition, Acrivon Therapeutics Inc saw -71.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ACRV
The total capital return value is set at -0.5. Equity return is now at value -54.07, with -48.11 for asset returns.
Based on Acrivon Therapeutics Inc (ACRV), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -18.02.
Currently, EBITDA for the company is -89.2 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.55.
Conclusion
In conclusion, Acrivon Therapeutics Inc (ACRV) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
